Innovotech (TSXV:IOT) Total Receivables : C$0.24 Mil (As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Innovotech Total Receivables?

Innovotech's Total Receivables for the quarter that ended in Sep. 2024 was C$0.24 Mil.

Innovotech Total Receivables Historical Data

The historical data trend for Innovotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovotech Total Receivables Chart

Innovotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Receivables

Get a 7-Day Free Trial

0.10

0.14

0.38

0.20

0.23

Innovotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Receivables	Get a 7-Day Free Trial															0.26	0.23	0.16	0.21	0.24

Innovotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Innovotech Total Receivables Related Terms

Thank you for viewing the detailed overview of Innovotech's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovotech Inc (TSXV:IOT) » Definitions » Total Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

2011 - 94 Street, Suite L131, Edmonton, AB, CAN, T6N 1H1

Website

https://www.innovotech.ca

Innovotech Inc is a Canada-based company that provides solutions to client biofilm problems through its biofilm contract research department. The core activities of the company are sales of its products, conducting contract research for outside customers, and research and development to identify products for future commercialization. The products of the company include human and fungal biofilm susceptibility tests, a seed treatment designed to combat bacterial and fungal diseases, and an assay used in growing microbial biofilms for research purposes. Geographically, the firm has a business presence in the United States, Canada, and the Rest of the world of which the majority of the revenue is derived from the United States.

Executives

James Gregory Timourian	Senior Officer
Alan Clyde Hayes Savage	10% Security Holder
Craig Milne	Director
David Shong-tak Tam	Director
Bernard Grobbelaar	Director